The share price reaction for ResMed implies that these drugs will have material uptake and reduce the long-term addressable market for CPAP. This is providing an opportunity to buy a high-quality business at a discount to its longer-term fundamental value.

What impressed or concerned you in this reporting season?

Why Hamish Tadgell just bought back into ResMed comes via ChinaTechNews.com.